BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26152085)

  • 21. Malignant melanoma-The cradle of anti-neoplastic immunotherapy.
    Koller KM; Wang W; Schell TD; Cozza EM; Kokolus KM; Neves RI; Mackley HB; Pameijer C; Leung A; Anderson B; Mallon CA; Robertson G; Drabick JJ
    Crit Rev Oncol Hematol; 2016 Oct; 106():25-54. PubMed ID: 27637351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
    Agarwala SS
    Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Normalization Cancer Immunotherapy for Melanoma.
    Vesely MD; Chen L
    J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of advanced or metastatic melanoma.
    Cebon J; Gedye C; John T; Davis ID
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in specific immunotherapy of malignant melanoma.
    Curiel-Lewandrowski C; Demierre MF
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 1):167-85; quiz 186-8. PubMed ID: 10906637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical management of melanoma.
    Brown CK; Kirkwood JM
    Surg Clin North Am; 2003 Apr; 83(2):283-322, viii. PubMed ID: 12744611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges.
    Millet A; Martin AR; Ronco C; Rocchi S; Benhida R
    Med Res Rev; 2017 Jan; 37(1):98-148. PubMed ID: 27569556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy.
    Kottschade L; Brys A; Peikert T; Ryder M; Raffals L; Brewer J; Mosca P; Markovic S;
    Melanoma Res; 2016 Oct; 26(5):469-80. PubMed ID: 27306502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of malignant melanoma.
    Kadison AS; Morton DL
    Surg Clin North Am; 2003 Apr; 83(2):343-70. PubMed ID: 12744613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New treatments for metastatic melanoma: a first hope].
    Robert C; Mateus C
    Rev Prat; 2011 Nov; 61(9 Suppl):S1-2. PubMed ID: 22338196
    [No Abstract]   [Full Text] [Related]  

  • 31. T cell receptor therapy against melanoma-Immunotherapy for the future?
    Winge-Main AK; Wälchli S; Inderberg EM
    Scand J Immunol; 2020 Oct; 92(4):e12927. PubMed ID: 32640053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for Melanoma.
    Albittar AA; Alhalabi O; Glitza Oliva IC
    Adv Exp Med Biol; 2020; 1244():51-68. PubMed ID: 32301010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of immunotherapy in the treatment of melanoma.
    Faries MB
    Surg Oncol Clin N Am; 2006 Apr; 15(2):399-418. PubMed ID: 16632223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The treatment of melanoma with an emphasis on immunotherapeutic strategies.
    Jack A; Boyes C; Aydin N; Alam K; Wallack M
    Surg Oncol; 2006 Jul; 15(1):13-24. PubMed ID: 16815006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging therapies for melanoma.
    Katipamula R; Markovic SN
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
    Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
    Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response.
    Gingrich AA; Kirane AR
    Surg Oncol Clin N Am; 2020 Jul; 29(3):467-483. PubMed ID: 32482321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
    Eggermont AM; Maio M; Robert C
    Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.